Published on November 6, 2009 at 1:01 AM
NovaDel Pharma Inc. (NYSE AMEX: NVD), today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology. Once issued, this patent will expire in 2018.
As previously announced, NovaDel’s Zolpimist ™ (zolpidem tartrate) 5 mg and 10 mg Oral Spray product is approved by the U.S. Food and Drug Administration (FDA) for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpimist is NovaDel’s second product approved by the FDA that uses NovaDel’s proprietary NovaMist oral spray technology. Zolpimist contains zolpidem tartrate, the same active ingredient as Ambien®, the world’s leading sedative hypnotic for the treatment of insomnia.
NovaDel maintains an extensive worldwide portfolio of intellectual property rights for select compounds using its pioneering oral spray delivery system. Upon issuance of the application, the Company will have been granted nine patents in the U.S., three patents in Canada and 66 patents throughout Europe, including Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden and Switzerland. Additionally, NovaDel has over 80 patents pending around the globe.
http://www.novadel.com/
12c44673-26f9-4585-b95f-d9bccc025435|0|.0
Posted in: Medical Patent News | Pharmaceutical News
Tags: Ambien, Amnesia, Angina, Biotechnology, Headache, Insomnia, Metabolism, Migraine, Nausea, Sedative, Sleep